source
- J&J invests $785M in Sail Biomedicines, secures option to buy for $2.58BJohnson & Johnson has agreed to pay $785 million up front to Sail Biomedicines, including a $465 million equity infusion and up to $140 million in milestone payments. The agreement also gives J&J a…
- Replimune's melanoma virus therapy wins FDA advisory committee vote after two rejectionsReplimune's oncolytic virus RP1, also called vusolimogene oderparepvec and Tudriqev, has been rejected twice by the FDA. Today an advisory committee voted 10 to 3 that the candidate shows enough ef…